Drug Type Small molecule drug |
Synonyms Albumin-bound docetaxel, Nab-docetaxel, ABI-008 + [4] |
Target |
Mechanism Tubulin inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pancreatic Cancer | Phase 3 | CN | 29 Jul 2024 | |
Squamous non-small cell lung cancer | Phase 3 | - | 01 May 2024 | |
Gastroesophageal junction adenocarcinoma | Phase 3 | CN | 15 Mar 2024 | |
stomach adenocarcinoma | Phase 3 | CN | 15 Mar 2024 | |
HER2 Positive Breast Cancer | Phase 3 | - | 01 Jul 2023 | |
c-Met positive non-small cell lung cancer | Phase 2 | - | 01 Jul 2024 | |
Locally Advanced Esophageal Squamous Cell Carcinoma | Phase 2 | CN | 01 Dec 2023 | |
Esophageal Squamous Cell Carcinoma | Phase 2 | CN | 27 Nov 2023 | |
Locally Advanced Lung Non-Small Cell Carcinoma | Phase 2 | CN | 27 Jun 2023 | |
Recurrent ovarian cancer | Phase 2 | CN | 18 Aug 2022 |
NCT05705635 (ASCO2024) Manual | Phase 2 | 125 | cnldnjfsnu(fmgmwxjgeq) = hhyjqwjbxz bdztzhcbfs (peypoxfzyi, 12.88 - 39.54) View more | Positive | 24 May 2024 | ||
cnldnjfsnu(fmgmwxjgeq) = zbtznqjknt bdztzhcbfs (peypoxfzyi, 6.20 - 28.31) View more | |||||||
NCT04931823 (ASCO2024) Manual | Phase 1 | 34 | qfksrasynn(lskgphbswh) = mqgsvjsllx xygghnoipu (hsjnzbmqpp ) View more | Positive | 24 May 2024 |